Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NSHO-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ensho to Present NSHO-101 Phase 1 Data for IBD at ECCO 2025
Details : EA1080 (NSHO-101) is an oral α4β7 integrin antagonist, small molecule drug candidate, which is being evaluated for the treatment of inflammatory bowel disease.
Product Name : EA1080
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2025
Lead Product(s) : NSHO-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable